Thiopurine adherence: a high prevalence with low impact on UC outcomes

Gómez-Medina, Concepción; Capilla-Lozano, María; Ballester-Ferré, María Pilar; Martí-Aguado, David; Crespo, Ana; Maia Bosca-Watts, Marta; Navarro-Cortés, Pablo; Antón, Rosario; Pascual-Moreno, Isabel; Tosca Cuquerella, Joan; Mínguez Pérez, Miguel.
Rev. esp. enferm. dig ; 114(2): 76-82, febrero 2022. tab, graf
Artículo en Inglés | IBECS (España) | ID: ibc-205547

Documentos relacionados

  1. Thiopurine adherence: a high prevalence with low impact on UC outcomes.
  2. Race, Genotype, and Azathioprine Discontinuation : A Cohort Study.
  3. Efficacy of optimised thiopurine therapy in patients with moderate-to-severe ulcerative colitis: retrospective long-term follow-up from two randomised trials.
  4. The c.415C>T polymorphism in NUDT15 is more frequent than the polymorphisms in TPMT in Chilean patients who use thiopurine drugs.
  5. Reducing risk in thiopurine therapy.
  6. Association of ITPA gene polymorphisms with adverse effects of AZA/6-MP administration: a systematic review and meta-analysis.
  7. Do clinical and laboratory parameters predict thiopurine metabolism and clinical outcome in patients with inflammatory bowel diseases?
  8. Poor Drug Sustainability in Inflammatory Bowel Disease Patients in Clinical Remission on Thiopurine Monotherapy.
  9. Azathioprine-induced alopecia: a rare adverse event, early marker of myelotoxicity.
  10. Feasibility of Reduced Clinical Monitoring in Patients with Inflammatory Bowel Disease Treated with Thiopurine Therapy.